Retrospective analysis of drug resistance of mycoplasma pneumoniae infection in children

FU Xiao-yan; QIN Xuan-guang; XIN De-li

doi:10.11852/zgetbjzz2017-25-09-26

PDF(553 KB)

Chinese Journal of Child Health Care ›› 2017, Vol. 25 ›› Issue (9) : 951-950. DOI: 10.11852/zgetbjzz2017-25-09-26

Retrospective analysis of drug resistance of mycoplasma pneumoniae infection in children

FU Xiao-yan,QIN Xuan-guang,XIN De-li

Author information +

History +

Abstract

Objective To investigate the prevalence and mecharism of drug resistance of mycoplasma pneumoniae (MP) of children in Beijing area in 2015-2016.Method A total of 89 respiratory throat swab specimens were collected from children with fever,cough or sore throat and other respiratory tract infection symptoms,admitted in Beijing Chaoyang Hospital Affiliated to Capital Medical University in 2015-2016.These cases were assayed mycoplasma culture and drug sensitivity test and were amplified by nested PCR method for identification of MP resistance loci.Results 53 cases were positive of mycoplasma pneumonia,with infection rate of 59%.18 cases were sensitive strains and drug resistance rate was 66%.32 strains showed A2063G point mutation in 23S rRNA domain V district.Both A2063G and A2064G point mutation existed in 3 cases.Conclusions Mycoplasma pneumoniae infection rate in Beijing area is prevalent.The macrolide resistance rate is rising and the main resistance mechanism is 23S rRNA domain V point mutation.

Key words

mycoplasma pneumonia / drug resistance / macrolides / resistant mechanism

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

FU Xiao-yan,QIN Xuan-guang,XIN De-li. Retrospective analysis of drug resistance of mycoplasma pneumoniae infection in children[J]. Chinese Journal of Child Health Care. 2017, 25(9): 951-950 https://doi.org/10.11852/zgetbjzz2017-25-09-26

References

[1] 殷勇,陆权,闫晓莉,等.肺炎支原体感染的流行病学[J].中华儿科杂志,2016,54(2):91-93.
[2] Liu Y,Ye X,Zhang H,et al.Antimicrobial susceptibility of mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai,China [J].Antimicrob Agents Chemother,2009,53(5):2160-2162.
[3] Xin D,Mi Z,Han X,et al.Molecular mechanisms of macrolide resistance in clinical isolates of mycoplasma pneumoniae from China [J].Antimicrob Agents Chemother,2009,53(5):2158-2159.
[4] Zhou Z,Li X,Chen X,et al.Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang,China [J].Antimicrob Agents Chemother,2015,59(2):1048-1051.
[5] Miyashita N,Oka M,Atypical Pathogen Study Group,et al.Macrolide-resistant mycoplasma pneumoniae in adults with community-acquired pneumonia[J].Int J Antimicrob Agents,2010,36(4):384-385.
[6] Kawai Y,Miyashita N,Yamaguchi T,et al.Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant mycoplasma pneumoniae pneumonia in paediatric patients[J].Respiratory,2012,17(2):354-362.
[7] Dumke R,von Baum H,Lück PC,et al.Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany[J].Clin Microbiol Infect,2010,16(6):613-616.
[8] Peuchant O,Ménard A,Renaudin H,et al.Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis[J].J Antimicrob Chemother,2009,64(1):52-58.
[9] Zheng X,Lee S,Selvarangan R,et al.Macrolide-resistant mycoplasma pneumoniae,United States[J].Emerg Infect Dis,2015,21(8):1470-1472.
[10] Eshaghi A,Memari N,Tang P,et al.Macrolide-resistant mycoplasma pneumoniae in humans,Ontario,Canada,2010-2011[J].Emerg Infect Dis,2013,19(9):1525-1527.
[11] Bébéar CM,Pereyre S.Mechanisms of drug resistance in Mycoplasma pneumoniae [J].Curr Drug Targets Infect Disord,2005,5(3):263-271.
[12] Waites KB,Duffy LB,Bbar CM,et al.Standardized methods andquality control limits for agar and broth microdilution susceptibility testingof mycoplasma pneumoniae,Mycoplasma hominis,and Ureaplaurealyticum[J].J ClinMicrobiol,2012,50(11):3542-3547.
[13] Akaike H,Miyashita N,Kubo M,et al.In vitro activities of 11 antimicrobialagents against macrolide-resistant mycoplasma pneumoniaeisolatesfrom pediatric patients:results from a multicenter surveillancestudy[J].Jpn J Infect Dis,2012,65(6):535-538.
[14] 刘禧杰,辛德莉,李靖,等,肺炎支原体对大环内酯类抗生素的耐药分子机制[J].实用儿科临床杂志,2008,23 (22):1730-1733.
[15] 辛德莉,靡祖煌,韩旭,等,应用巢式聚合酶链反应和测序检测肺炎支原体23S rRNA 中点突变[J].中华儿科杂志,2008,46(7):522-525.
[16] 李靖,崔菲菲,辛德莉,等.儿童呼吸道肺炎支原体感染耐药现状[J].实用儿科临床杂志,2009,24(22):1717-1719.
[17] Xin D,Mi Z,Han X,et al.Molecular mechanisms of macrolide resistance in clinical isolates of mycoplasma pneumoniae from China[J].Antimicmb Agents Chemother,2009,53(5):2158-2159.
[18] Liu Y,Ye X,Zhang H,et al.Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis on macrolide-resisant strains from Shanghai China[J].Antimicrobial Agents and Chemotherapy,2009,53(5):2160-2163.
[19] 韩晓华,路素坤,李书秀,等.肺炎支原体23SrRNA基因突变及其所致肺炎的临床分析[J].中国医科大学学报,2011,40(2):162-165.
[22] 李静宜,孙岚,秦选光,等.实时定量PCR检测肺炎支原体2063位点点突变的方法学研究[J].中国全科医学,2013,16 (11):3774-3777.